Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
Tadahisa Numakura, Koji Murakami, Tsutomu Tamada, Chiaki Yamaguchi, Chihiro Inoue, Shinya Ohkouchi, Naoki Tode, Hirohito Sano, Hiroyuki Aizawa, Kei Sato, Ayumi Mitsune, Hajime Kurosawa, Toru Nakazawa, Hisatoshi Sugiura
Author information
JOURNAL OPEN ACCESS

2022 Volume 61 Issue 20 Pages 3101-3106

Details
Abstract

BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

Content from these authors
© 2022 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top